Girish Mahajan (Editor)

BioCryst Pharmaceuticals

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Public (NASDAQ: BCRX)

Products
  
Biotechnology

Net income
  
US$-39.1M (FY 2012)

Founder
  
Charles Bugg

Industry
  
Healthcare

Operating income
  
US$-33.9M (FY 2012)

Revenue
  
26.3 million USD (2012)

Founded
  
1986

Key people
  
Jon P. Stonehouse , President and Chief Executive Officer Thomas Staab II, Chief Financial Officer

Stock price
  
BCRX (NASDAQ) US$ 6.86 +0.62 (+9.94%)1 Mar, 4:00 PM GMT-5 - Disclaimer

Headquarters
  
Durham, North Carolina, United States

Biocryst pharmaceuticals inc bcrx stock chart technical analysis for 02 27 17


BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Durham, North Carolina. The company focuses on orphan & autoimmune diseases, and antivirals. The company's most advanced drug candidate is the antiviral Peramivir, which is approved in Japan, Korea and China. It was authorized by the FDA for emergency use in the treatment of patients hospitalized with influenza during the 2009-10 influenza A virus subtype H1N1 pandemic.

Contents

Biocryst pharmaceuticals inc bcrx stock chart technical analysis for 12 19 16


History

The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.

In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.

BioCryst is a member of the Alliance for Biosecurity, a group of companies that work to develop vaccines and other measures that can be used in the case of a pandemic or bioterrorism attack.

Pipeline

  • Peramivir is an intravenous (i.v.) antiviral drug being developed for the treatment of influenza. BioCryst expects to file for FDA approval before the end of 2013.
  • BCX4161 is an orally administered inhibitor of plasma kallikrein entering Phase 2 development to prevent attacks in hereditary angioedema (HAE) patients.
  • BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity for multiple viruses. Development of BCX4430 is funded under a U.S. Government contact of up to $22 million granted by the National Institute of Allergy and Infectious Diseases (NIAID) in September 2013.
  • Forodesine HCl, investigational purine nucleoside phosphorylase (PNP) inhibitor for the treatment of T- and B-cell mediated disorders licensed to Mundipharma Research Ltd in Phase 2 development.
  • BCX4208 is a second generation purine nucleoside phosphorylase inhibitor for the treatment of gout that has successfully completed Phase 2 development.
  • References

    BioCryst Pharmaceuticals Wikipedia